Research Topics
| Henry KrumSummaryAffiliation: Monash University Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugsHenry Krum
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Cardiovasc Ther 30:342-50. 2012....- Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndromeSuree Lekawanvijit
Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Am J Physiol Heart Circ Physiol 302:H1884-93. 2012..In conclusion, renal impairment occurs early post-MI and is associated with hemodynamic and structural changes in the kidney possibly via activation of the Smad2 signaling pathway... 
2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006Henry Krum
Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic
Med J Aust 194:405-9. 2011..While patient circumstances and clinical judgement should guide the interpretation of these findings in the clinical context, this update, together with the 2006 guidelines, provides current clinical guidance on CHF...- Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudyHenry Krum
Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University Alfred Hospital, Melbourne, Victoria, Australia
Circ Heart Fail 4:561-8. 2011..Myocardial fibrosis is a key pathological feature of HFPEF. Peripheral collagen markers may reflect this excess fibrosis; however, the relation of these markers to prognosis in patients with HFPEF has not as yet been determined... - Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophyAndrew R Kompa
Department of Medicine, Monash University, Alfred Hospital, Victoria, Australia
Peptides 31:1523-30. 2010..We hypothesize that other neurohumoral pathways may have a greater involvement in the pathogenesis of this model. Targeting the UII system appears to be insufficient to observe a beneficial outcome... - Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL studyHenry Krum
Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia
J Hypertens 27:886-93. 2009..To evaluate the hypertensive effects of etoricoxib and diclofenac relative to baseline hypertension risk factors in arthritis patients... - Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunctionArintaya Phrommintikul
Dept of Epidemiology and Preventive Medicine, Monash University, Melbourne VIC 3004, Australia
Am J Physiol Heart Circ Physiol 294:H1804-14. 2008..7%; P < 0.05), GSK 3 (23.8%; P < 0.01), and ramipril (35.5%; P < 0.01) treatment. These results suggest that ROCK inhibition improves LV geometry and reduces collagen deposition accompanied by improved diastolic function in POH... - Impact of home versus clinic-based management of chronic heart failure: the WHICH? (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care) multicenter, randomized trialSimon Stewart
Preventative Health, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
J Am Coll Cardiol 60:1239-48. 2012..The goal of this study was to make a head-to-head comparison of 2 common forms of multidisciplinary chronic heart failure (CHF) management... 
Renal denervation in moderate to severe CKDDagmara Hering
Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
J Am Soc Nephrol 23:1250-7. 2012..In conclusion, this study suggests a favorable short-term safety profile and beneficial BP effects of catheter-based renal nerve ablation in patients with stage 3-4 CKD and resistant hypertension...- Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in ratsLavinia Tran
Department of Epidemiology and Preventive Medicine, National Health Medical Research Council Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia
Am J Physiol Heart Circ Physiol 298:H608-13. 2010..Chronic U-II infusion causes diastolic dysfunction, caused by fibrosis of the LV. The in vitro data suggest that this may be in part occurring via a ROCK-dependent pathway... - Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS studyHenry Krum
Monash University, Melbourne, Australia
Am Heart J 151:55-61. 2006..We therefore examined this question in the COPERNICUS study of 2289 patients with severe CHF receiving the beta1-beta2/alpha1 blocker carvedilol compared with placebo... - Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS IIHenry Krum
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Cardiology 108:28-34. 2007.... - Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosteroneBing H Wang
Centre for Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Clin Exp Pharmacol Physiol 37:912-8. 2010..6. These results demonstrate a potential antiremodelling effect of selective COX-2 inhibitors in the setting of RAAS stimulation in cardiac cells, whereas naproxen has no effect... - Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarctionAndrew J Boyle
Department of Medicine, St Vincent s Hospital, University of Melbourne, Melbourne, Princes Street, Fitzroy 3065, Vic, Australia
J Mol Cell Cardiol 39:213-21. 2005..PKC-inhibition with ruboxistaurin led to attenuation in both the pathological fibrosis and impaired cardiac function that follow experimental MI, suggesting a possible role for this agent in preventing post-infarction heart failure... - Evaluation of the effects of urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patientsLavinia Tran
Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
Cardiovasc Ther 30:295-300. 2012..However, the mechanism of action remains unclear. The role of soluble epoxide hydrolase (sEH) as a mediator of UII in the vasculature has not been explored... - Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?Tai Juan Aw
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia
J Hypertens 24:1979-84. 2006..Rofecoxib is uniquely metabolized by cytosol reductase and may compete with aldosterone for metabolism. We hypothesized that the effect of rofecoxib on BP may be due to an increase in aldosterone levels... - Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL programHenry Krum
Department of Epidemiology and Preventive Medicine, NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University, Alfred Hospital, Melbourne VIC 3004, Australia
Eur J Heart Fail 11:542-50. 2009..Non-steroidal anti-inflammatory drugs have been associated with increased risk of congestive heart failure (CHF). We aimed to assess the impact of treatment with etoricoxib or diclofenac on risk of CHF relative to baseline risk factors... - Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertensionDagmara Hering
Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 8008, Australia
Hypertension 61:457-64. 2013..Whether the earlier changes in single-unit firing patterns may predict long-term BP response to RDN warrants further exploration... - Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trialsIngrid Hopper
Department of Clinical Pharmacology, Alfred Hospital, Melbourne, Australia
Eur J Cardiovasc Prev Rehabil 18:813-23. 2011..We therefore sought to determine whether interventions (including diet, exercise and pharmacological therapy), altered all-cause and cardiovascular related mortality in such subjects... - Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathyDarren J Kelly
Department of Medicine, University of Melbourne, St Vincent s Hospital, Victoria, Australia
Am J Physiol Heart Circ Physiol 293:H2860-9. 2007..While tranilast did not affect Smad phosphorylation, it significantly attenuated TGF-beta-induced p44/42 mitogen-activated protein kinase phosphorylation... - In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodellingJennifer Martin
National Health and Medical Research Council of Australia Centre for Clincial Research and Excellence in Therapeutics, Epidemiology and Preventive Medicine, Monash University Alfred Hospital, Melbourne, Victoria, Australia
Clin Exp Pharmacol Physiol 32:697-701. 2005..4. Atorvastatin appears to directly inhibit collagen production by cardiac fibroblasts. This antifibrotic action may contribute to the antiremodelling effect of statins... - Circuit resistance training in chronic heart failure improves skeletal muscle mitochondrial ATP production rate--a randomized controlled trialAndrew D Williams
Centre for Ageing, Rehabilitation, Exercise and Sport, Victoria University of Technology, Melbourne, Australia
J Card Fail 13:79-85. 2007..We aimed to determine the role of skeletal muscle mitochondrial ATP production rate (MAPR) in relation to exercise tolerance after resistance training (RT) in chronic heart failure (CHF)... - Renal denervation and hypertensionMarkus P Schlaich
Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute and Heart Centre, Alfred Hospital, Melbourne, Australia
Am J Hypertens 24:635-42. 2011..Here we briefly review the science surrounding renal denervation, summarize the current data on safety and efficacy of renal nerve ablation, and discuss some of the open questions that need to be addressed in the near future... - Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-betaJennifer Martin
University of Melbourne, Department of Medicine, St. Vincent's Hospital, Victoria, Australia
Cardiovasc Res 65:694-701. 2005..01). CONCLUSION: These findings indicate that tranilast has antifibrotic actions in the Ren-2 model of experimental diabetic cardiac disease by mechanisms that might attributable to reduced TGF-beta activity... - Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trialsHendrik Zimmet
Monash Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Rd, Melbourne, VIC 3004, Australia
Eur J Heart Fail 14:91-105. 2012..Studies have provided conflicting results. We therefore performed a meta-analysis of these treatments, examining short- and long-term efficacy and safety... - Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE studyEmma Ashton
Department of Health Science, Monash University, Frankston Vic 3119, Melbourne, Australia
Int J Cardiol 146:404-7. 2011..These agents may also possess additional properties, independent of effects on blood lipid levels, which may have an effect on cardiac remodeling. However, beneficial effects were not observed in the recent UNIVERSE trial... - Reduced exercise tolerance in CHF may be related to factors other than impaired skeletal muscle oxidative capacityAndrew D Williams
Centre for Rehabilitation, Exercise and Sport Science, Victoria University of Technology, Melbourne, Australia
J Card Fail 10:141-8. 2004..Therefore, we hypothesize that the low VO(2peak) observed in CHF patients may be the result of fiber atrophy and possibly impaired activation of oxidative phosphorylation... - Coenzyme Q10 in cardiovascular diseaseSalvatore Pepe
CJOB Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia
Mitochondrion 7:S154-67. 2007..3. Presently, due to the notable absence of clinically significant side effects and likely therapeutic benefit, CoQ(10) can be considered a safe adjunct to standard therapies in cardiovascular disease... - Health-related quality of life after renal denervation in patients with treatment-resistant hypertensionGavin W Lambert
Human Neurotransmitters, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
Hypertension 60:1479-84. 2012..In this pre- and post-hypothesis generating study, several aspects of QoL were improved after renal denervation; however, this was not directly associated with the magnitude of BP reduction... - Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastographyIngrid Hopper
Department of Clinical Pharmacology and Therapeutics, The Alfred Center, Melbourne, Australia
Eur J Heart Fail 14:621-7. 2012..We examined the impact of cardiac dysfunction on LSM using FibroScan(®) and the influence of volume changes on LSM... - Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in ratsWilliam Kemp
Department of Epidemiology and Preventive Medicine, Monash University, Prahran, Victoria, Australia
Am J Physiol Gastrointest Liver Physiol 297:G762-7. 2009..This response may be mediated via induction of fibrogenic cytokines. These findings have pathophysiological implications in human liver disease where increased plasma UII levels have been observed... - Urotensin II levels are an important marker for the severity of portal hypertension in childrenReshma Pawar
Department of Paediatrics, University of Melbourne, Melbourne, Australia
J Pediatr Gastroenterol Nutr 53:88-92. 2011..In this study, we aimed to determine whether U-II levels in healthy children are ontogenically regulated and we explored the effect of chronic liver disease on peripheral circulating U-II levels... - Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failureHenry Krum
Monash University, Alfred Hospital, Melbourne, Victoria, Australia
J Card Fail 13:1-7. 2007..However, chronic heart failure (CHF) patients were often excluded in such trials. Statins possess pharmacologic properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients... - Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertensionBrigitte Sondermeijer
Department of Medicine, Monash University, The Alfred Hospital, Commercial Road, Melbourne, Victoria 3004, Australia
Am J Hypertens 18:1195-9. 2005..CONCLUSIONS: The demonstration of opposing effects of exogenous U-II in patients with hypertension and normal subjects suggests that U-II may be contributory to the increased vascular tone of these patients... - Cardiorenal syndrome: the emerging role of protein-bound uremic toxinsSuree Lekawanvijit
Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Victoria 3004, Australia
Circ Res 111:1470-83. 2012..Potential mechanisms underlying indoxyl sulfate-induced cardiorenal fibrosis are discussed. Future research and clinical implications conclude this review... - Sustained activation of microglia in the hypothalamic PVN following myocardial infarctionMelissa Dworak
School of Medical Sciences, and Health Innovations Research Institute, RMIT University, Melbourne, Australia
Auton Neurosci 169:70-6. 2012.... - Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSHenry Krum
Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Alfred Hospital, Melbourne VIC 3004, Australia
Eur J Heart Fail 13:107-14. 2011..Perspective The ATMOSPHERE study will definitively determine the role of a DRI strategy additional to or as an alternative to conventional RAAS blockade in patients with chronic systolic HF... - B-type natriuretic peptide testing and the accuracy of heart failure diagnosis in the emergency departmentAmaali Lokuge
Emergency and Trauma Centre, Melbourne, Victoria, Australia
Circ Heart Fail 3:104-10. 2010..This study assessed whether B-type natriuretic peptide (BNP) testing in these patients improved the accuracy of HF diagnosis... - Recent advances in the treatment of hypertensionDagmara Hering
Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road Central, Melbourne, Victoria 8008, Australia
Expert Rev Cardiovasc Ther 9:729-44. 2011..Several novel pharmacological- and device-based approaches have recently been tested and may prove helpful to achieve better blood pressure control rates and thereby improve cardiovascular outcomes in patients with hypertension... - Renal sympathetic nerve ablation: the new frontier in the treatment of hypertensionMarkus P Schlaich
Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, St Kilda Road Central, Melbourne, Victoria 8008, Australia
Curr Hypertens Rep 12:39-46. 2010..Accordingly, renal sympathetic nerve ablation appears to be a logical therapeutic approach for the treatment of hypertension. Recent reports on a novel catheter-based renal nerve ablation procedure reviewed in this article are promising... - Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFTHenry Krum
Monash University Medical School, Alfred Hospital, Melbourne, Australia
Eur J Heart Fail 6:937-45. 2004..To investigate the effect of valsartan in the Valsartan-Heart Failure Trial (Val-HeFT) when added to angiotensin-converting enzyme inhibitor (ACEi) alone in patients with heart failure (HF)... - Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the second Australian National Blood Pressure Study (ANBP2)Mark R Nelson
Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Prahran, Australia
Am J Hypertens 16:39-45. 2003..The identification of simple predictors would assist the family physician to select who may or may not have their medication ceased... - Fibrosis as a therapeutic target post-myocardial infarctionFiona See
National Health and Medical Research Council of Australia Centre of Clinical Research Excellence in Therapeutics, Monash University, Alfred Hospital, Melbourne Victoria 3004, Australia
Curr Pharm Des 11:477-87. 2005..Furthermore, specific anti-fibrotic drugs have been developed and are currently being explored for these and other cardiac conditions where pathological ECM deposition is felt to be contributory to disease progression... - Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trialWilliam Kemp
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Liver Int 29:427-33. 2009..Aims: To examine the impact of SID with norfloxacin on portal pressure in subjects with clinically significant portal hypertension and explore the potential mechanisms by which norfloxacin exerts its haemodynamic effects... - Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trialMurray D Esler
Baker IDI Heart and Diabetes Institute, 75 Commercial Rd, Melbourne, Victoria 3004, Australia
Circulation 126:2976-82. 2012..Longer-term follow-up, including 6-month crossover results, is now presented... - Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfateSuree Lekawanvijit
Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
PLoS ONE 7:e41281. 2012..05) despite no significant change in LV function. In conclusion, STNx resulted in increased cardiac fibrosis and circulating IS levels. Reduction of IS with AST-120 normalizes cardiac fibrosis, in a blood pressure independent manner... - Renal denervation in human hypertension: mechanisms, current findings, and future prospectsMarkus P Schlaich
Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, P O Box 6492, St Kilda Road Central, Melbourne, Victoria, 8008, Australia
Curr Hypertens Rep 14:247-53. 2012..Herein we review the current findings and assess whether these high hopes are justified... - Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophyAlex Tzanidis
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of MedicineEpidemiology and Preventive Medicine, Monash University Medical School, Prahran, Victoria, Australia
Circ Res 93:246-53. 2003.... - Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-βAmanda J Edgley
Department of Medicine, St Vincent s Hospital, University of Melbourne, Victoria, Australia
Cardiovasc Ther 30:e30-40. 2012..This review focuses on the therapeutic targeting of TGF-β in the prevention of pathological fibrosis in the heart... - Cardiovascular role of urotensin II: effect of chronic infusion in the ratAndrew R Kompa
NHMRC Centre of Clinical Research Excellence in Therapeutics, Departments of Medicine and Epidemiology and Preventive Medicine, Central and Eastern Clinical School, Monash University, Alfred Hospital, Commercial Road, Prahran, VIC 3181, Australia
Peptides 25:1783-8. 2004.... - Aldosterone receptor antagonists for hypertension: what do they offer?Danny Liew
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria, Australia
Drugs 63:1963-72. 2003..Perhaps most notably, eplerenone was generally well tolerated, and did not cause the antiandrogenic and progestational adverse effects commonly observed with spironolactone... - Prognostic benefit of beta-blockers in patients not receiving ACE-InhibitorsHenry Krum
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne 3004, Australia
Eur Heart J 26:2154-8. 2005..The magnitude of the prognostic benefit of BBs in the absence of ACE-I or ARB has not as yet been determined... - Chronic heart failure--optimising care in general practiceLeon Piterman
School of Primary Health Care, Monash University, Victoria, Australia
Aust Fam Physician 34:547-53. 2005..In Australia, over 300 000 people are affected by CHF. Quality general practice forms the cornerstone for early diagnosis and evidence based integrated care... - Urotensin II in chronic liver disease: in vivo effect on vascular toneWilliam Kemp
Department of Gastroenterology, Alfred Hospital, Melbourne, Australia
Scand J Gastroenterol 43:103-9. 2008..The objective of this study was to investigate the role of UII in liver cirrhosis via examination of the in vivo effect of UII in this patient group... - Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertensionWilliam Kemp
Department Gastroenterology, Alfred Hospital, Melbourne, Australia
Liver Int 27:1232-9. 2007..Urotensin II (UII) is recognised as the most potent human vasoconstrictor; however, its role in chronic liver disease (CLD) is unknown... - Eplerenone in the treatment of chronic heart failureHenry Krum
Department of Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria 3004, Australia
Expert Rev Cardiovasc Ther 2:315-20. 2004..Due to the fact that eplerenone is a selective aldosterone receptor antagonist, it does not cause troublesome hormonal side effects. This is an important feature of the drug that is likely to help maintain compliance... - Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertensionHenry Krum
National Health and Medical Research Council of Australia, Centre of Clinical Research Excellence in Therapeutics, Monash University, Melbourne, VIC 3004, Australia
Am J Physiol Heart Circ Physiol 290:H1706-12. 2006..We conclude that sympathetic nervous inhibition is not a major component of the blood pressure-lowering action of ARBs in essential hypertension... - Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?Pornwalee Porapakkham
Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Australia
Cardiovasc Ther 28:93-100. 2010..Therefore, achieving an absolute HR or change in HR with BBs may be more important than target dose in maximizing benefits of BBs in this setting... - Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFTHenry Krum
NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University, Melbourne, Australia
Int J Cardiol 119:48-53. 2007..To address this, we retrospectively analyzed the Valsartan Heart Failure Trial (Val-HeFT) database to determine outcomes in CHF patients according to statin use at baseline... - Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006Henry Krum
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, and Department of Medicine, Monash University, Alfred Hospital, Melbourne, Vic, Australia
Med J Aust 185:549-57. 2006..Management involves prevention, early detection, amelioration of disease progression, relief of symptoms, minimisation of exacerbations, and prolongation of survival... - Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disordersHenry Krum
NHMRC Centre of Clinical Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Alfred Hospital, Central and Eastern Clinical School, Melbourne, Victoria 3004, Australia
J Hypertens 25:25-35. 2007..Finally, ACE2 augmentation, antisense gene strategies, and vaccination against the renin-angiotensin system should still be considered experimental, but have significant appeal as additional approaches to the blockade of this system... - Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trialsHenry Krum
Monash University Alfred Hospital, Melbourne, Victoria 3004, Australia
Cardiovasc Ther 28:124-32. 2010.... - Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort studyHenry Krum
Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
Lancet 373:1275-81. 2009.... - Blood pressure effects of COX-2 inhibitorsHenry Krum
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
J Cardiovasc Pharmacol 47:S43-8. 2006..Such studies have recently been announced and will commence soon... - Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?Suree Lekawanvijit
Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Alfred Hospital, Melbourne, VIC 3004, Australia
Eur Heart J 31:1771-9. 2010..The aim of this study was to determine direct effects of IS on cardiac cells as well as the pro-inflammatory effect of IS... - Microglia activation in the hypothalamic PVN following myocardial infarctionIndrajeetsinh Rana
School of Medical Sciences, RMIT University, Melbourne, Australia
Brain Res 1326:96-104. 2010..The activated microglia may contribute to the increased local production of pro-inflammatory cytokines observed in the PVN after myocardial infarction and resulting in reduced left ventricular function... - Statins and clinical outcomes in heart failureJennifer H Martin
University of Melbourne Department of Medicine, St Vincent s Hospital, Melbourne, Vic, Australia
Clin Sci (Lond) 113:119-27. 2007.... - Therapeutic potential of blockade of the urotensin II system in systemic hypertensionHenry Krum
Department of Epidemiology and Preventive Medicine, Monash University Alfred Hospital, 89 Commercial Road, Melbourne, VIC 3004, Australia
Curr Hypertens Rep 9:53-8. 2007..Early preclinical and clinical studies report potential beneficial effects in renal disease, heart failure, and diabetes, although effects on blood pressure have been equivocal... - Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressureTai-Juan Aw
Department of Clinical Pharmacology, Monash University, Alfred Hospital, Melbourne, Victoria 3004, Australia
Arch Intern Med 165:490-6. 2005..These BP elevations may be clinically significant in relation to increased cardiovascular risk... - Extending the boundaries of cardiac resynchronization therapy: efficacy in atrial fibrillation, New York heart association class II, and narrow QRS heart failure patientsSara Wein
Alfred Hospital, Melbourne, Australia
J Card Fail 16:432-8. 2010..However, additional patient groups may also benefit from CRT... - Eplerenone. PharmaciaDanny Liew
National Health and Medical Research Council, Department of Epidemiology, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria 3004, Australia
Curr Opin Investig Drugs 4:316-22. 2003..The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial... - New developments in the pharmacological treatment of chronic heart failureHenry Krum
Department of Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria 3004, Australia
Expert Opin Investig Drugs 12:751-7. 2003..That the mortality and morbidity of patients with chronic heart failure remain unacceptably high makes the ongoing commitment to exploration of new drug therapies for the condition critical... - Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockersGenevieve Flannery
Clinical Pharmacology Unit, Alfred Hospital, Melbourne, Australia
Am J Cardiol 101:865-9. 2008..Therefore, the magnitude of HR reduction may be more important than the achievement of target dose in beta-blocker treatment of systolic CHF... - Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trialsSteven Joseph Haas
NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia
Am Heart J 146:848-53. 2003.... - Factors influencing family physician adherence to hypertension treatment guideline recommendations on the initiation of pharmacotherapy: questionnaire surveyMark R Nelson
Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Prahran, Australia
Am J Cardiovasc Drugs 3:437-41. 2003.... - Urotensin II: a vascular mediator in health and diseaseWilliam Kemp
Department of Epidemiology and Preventive Medicine, NHMRC Centre of Clinical Research Excellence in Therapeutics, Monash University, Burnet Institute, Prahran 3181, Australia
Curr Vasc Pharmacol 3:159-68. 2005.... - Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency settingLouisa L Lam
Monash University, Melbourne, Victoria, Australia
Ann Intern Med 153:728-35. 2010..Although the accuracy of B-type natriuretic peptide (BNP) testing for diagnosing acute decompensated heart failure has been extensively evaluated, the effect of this test on clinical outcomes remains unclear... - Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II studyHenry Krum
NHMRC Centre for Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, 3rd Floor, Burnet Tower, AMREP Precinct, Commercial Road, Melbourne VIC 3004, Australia
Eur J Heart Fail 8:302-7. 2006..However, there remains concern regarding tolerability of these agents in the elderly, which has contributed to the limited uptake of these agents in clinical practice... - Pharmacologic management of the cardiorenal syndrome in heart failureHenry Krum
Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University and Alfred Hospital, 89 Commercial Road, Melbourne, Victoria 3004, Australia
Curr Heart Fail Rep 6:105-11. 2009..Furthermore, device-based approaches such as ultrafiltration may also play an important therapeutic role...